Table of Contents
Journal of Cancer Research
Volume 2014, Article ID 982080, 7 pages
http://dx.doi.org/10.1155/2014/982080
Research Article

Impact of Immunochemotherapy-Related Hepatic Toxicity on the Outcome of HCV-Positive Diffuse Large B-Cell Lymphoma Patients

1Department of Medical Oncology, Faculty of Medicine, Zagazig University, Sharkia 44519, Egypt
2Department of Internal Medicine, Faculty of Medicine, Zagazig University, Sharkia 44519, Egypt

Received 16 August 2014; Revised 4 November 2014; Accepted 4 November 2014; Published 30 November 2014

Academic Editor: Takahiro Yamauchi

Copyright © 2014 Fouad Abu-Taleb et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. A. L. Zignego, C. Giannini, and L. Gragnani, “HCV and lymphoproliferation,” Clinical and Developmental Immunology, vol. 2012, Article ID 980942, 8 pages, 2012. View at Publisher · View at Google Scholar · View at Scopus
  2. B. Coiffier, E. Lepage, J. Brière et al., “CHOP chemotherapy plus rituximab compared with chop alone in elderly patients with diffuse large-B-cell lymphoma,” The New England Journal of Medicine, vol. 346, no. 4, pp. 235–242, 2002. View at Publisher · View at Google Scholar · View at Scopus
  3. M. Pfreundschuh, L. Trümper, A. Österborg et al., “CHOP-like chemotherapy plus rituximab versus CHOP-like chemotherapy alone in young patients with good-prognosis diffuse large-B-cell lymphoma: a randomised controlled trial by the MabThera International Trial (MInT) Group,” The Lancet Oncology, vol. 7, no. 5, pp. 379–391, 2006. View at Publisher · View at Google Scholar · View at Scopus
  4. Y. Tsutsumi, Y. Yamamoto, J. Tanaka, M. Asaka, M. Imamura, and N. Masauzi, “Prevention of hepatitis B virus reactivation under rituximab therapy,” Immunotherapy, vol. 1, no. 6, pp. 1053–1061, 2009. View at Publisher · View at Google Scholar · View at Scopus
  5. C. A. Heid, J. Stevens, K. J. Livak, and P. M. Williams, “Real time quantitative PCR,” Genome Research, vol. 6, no. 10, pp. 986–994, 1996. View at Publisher · View at Google Scholar · View at Scopus
  6. H. Nishikawa, M. Tsudo, and Y. Osaki, “Clinical outcome in diffuse large B-cell lymphoma with hepatitis C virus infection in the rituximab era: a single center experience,” Oncology Reports, vol. 28, no. 3, pp. 835–840, 2012. View at Publisher · View at Google Scholar · View at Scopus
  7. D. Ennishi, Y. Maeda, N. Niitsu et al., “Hepatic toxicity and prognosis in hepatitis C virus-infected patients with diffuse large B-cell lymphoma treated with rituximab-containing chemotherapy regimens: a Japanese multicenter analysis,” Blood, vol. 116, no. 24, pp. 5119–5125, 2010. View at Publisher · View at Google Scholar · View at Scopus
  8. C. Besson, D. Cantoni, E. Lepage et al., “Characteristics and outcome of diffuse large B-cell lymphoma in hepatitis C virus-positive patients in LNH 93 and LNH 98 groupe d'etude des lymphomes de l'adulte programs,” Journal of Clinical Oncology, vol. 24, no. 6, pp. 953–960, 2006. View at Publisher · View at Google Scholar · View at Scopus
  9. C. Visco, L. Arcaini, E. Brusamolino et al., “Distinctive natural history in hepatitis C virus positive diffuse large B-cell lymphoma: analysis of 156 patients from northern Italy,” Annals of Oncology, vol. 17, no. 9, pp. 1434–1440, 2006. View at Publisher · View at Google Scholar · View at Scopus
  10. M. Merli, C. Visco, M. Spina et al., “Outcome prediction of diffuse large B-cell lymphomas associated with hepatitis C virus infection: a study on behalf of the Fondazione Italiana Linfomi,” Haematologica, vol. 99, no. 3, pp. 489–496, 2013. View at Publisher · View at Google Scholar
  11. L. Nosotti, M. D'Andrea, A. Pitidis et al., “Hepatitis C virus infection prevalence and liver dysfunction in a cohort of B-cell non-Hodgkin's lymphoma patients treated with immunochemotherapy,” Scandinavian Journal of Infectious Diseases, vol. 44, no. 1, pp. 70–73, 2012. View at Publisher · View at Google Scholar · View at Scopus
  12. M. Marignani, M. Mangone, M. C. Cox et al., “HCV-positive status and hepatitis flares in patients with B-cell non-Hodgkin's lymphoma treated with rituximab-containing regimens,” Digestive and Liver Disease, vol. 43, no. 2, pp. 139–142, 2011. View at Publisher · View at Google Scholar · View at Scopus
  13. F. Boyle and E. Reid, “Viral reactivation and clinical hepatitis in patients with hepatitis C who receive rituximab as part of chemotherapy for treatment of lymphoma: a case series,” Journal of Clinical Oncology, vol. 28, supplement, abstract e18559, 2010. View at Google Scholar
  14. D. Ennishi, Y. Terui, M. Yokoyama et al., “Monitoring serum hepatitis C virus (HCV) RNA in patients with HCV-infected CD20-positive B-cell lymphoma undergoing rituximab combination chemotherapy,” American Journal of Hematology, vol. 83, no. 1, pp. 59–62, 2008. View at Publisher · View at Google Scholar · View at Scopus